Pharmaceutical Industry in India has witnessed a significant up-surge and enjoys an important position in the global pharmaceuticals sector today. Low cost of production and R&D has been the major driver behind the growth of pharmaceutical companies in India. Furthermore, the Government has been supporting all phases of manufacturing processes for the pharmacy industry in export and is also working towards self-procurement of APIs and other RM rather than depending on countries outside India.
The ongoing innovation in the Indian pharma industry has paved the way for contract manufacturers to develop new therapeutic products and generic medicines which will further steer the industry ahead to greater heights. However, ensuring excellence in safety and quality has become more critical than ever when it comes to products and services deliver-ability in the pharmaceutical industry. Hence, a competent player who is well positioned to cater the global demand of standardized medicines at a low cost will propel the Indian Pharmaceutical Industry even further.
With an unparalleled experience of 50+ years, Medopharm is one of the most trusted and leading pharmaceutical contract manufacturing companies in India with expertise in cardiology, CNS, antibiotics, and generics. The company has been successfully developing and manufacturing pharmacy products which are cost-effective and quality-driven. Medopharm is currently catering to more than 100+ countries across Africa, Asia,
Europe and Central America, to name a few. This is due to its strong wide distribution network in the international pharmaceutical market.
Ensuring Quality & Reliability
Medopharm thoroughly assures its partners and customers with excellent safety record,
excellent quality assurance, secure supply chain, high-quality products, innovative pharmaceutical services, technical mastery and expertise in contract manufacturing. Medopharm has been working across all products in the beta-lactam and non-beta-lactam segments. This is backed by its decades of experience and expertise in Pharmaceutical manufacturing, packaging and exports. Furthermore, the company’s facility is approved by multiple regulatory boards such as UKMHRA, cGMP and Ministry of Health from many countries.
And when it comes meeting the standards, quality checks are done at every step of the product development. Their facilities can produce tablets, capsules, and dry syrups, wherein Medopharm is the only company in India that uses aqueous coating technology on tablets on coamoxiclav tablets. Medopharm has also been offering Co-branding services to help pharmacy companies build robust brand relationships and enhance the brand equity. This also helps in building adequate brand awareness in the market while reducing the operational and marketing costs. And to top it off, it enables the growth of the customer base and acquisition through positive consumer perception.
We import the raw materials from internationally accredited sources approved by various bodies like USFDA, EU, GMP etc thereby ensuring the products manufactured are of the highest quality
State-of-the-art Manufacturing Capabilities
The company has three state-of-the-art manufacturing facilities which have been specifically designed and developed to meet the ever-growing demand for high-quality products in the Pharmaceutical Industry. These facilities are integrated with latest technology and high-tech machines to continuously work on bringing the needed innovation in the market through its products and services.
"Medopharm is one of the few companies to has procured a unique tropical blister pack (Tro-Pack) from IWK (IWK Verpackungstechnik, Germany) for some of its temperature and moisture sensitive materials. We import the raw materials from internationally accredited sources approved by the US Foods and Drug Administration (FDA), thereby ensuring the products manufactured are of the highest quality. Going forward, we will be targeting becoming one of the largest generic contract manufacturing in India by increasing the presence on untapped market,” concludes Udhan Kumar Chordia, CEO at Medopharm.